0001376793 2026-07-01 2026-09-30 0001376793 2026-10-27 0001376793 2026-09-30 0001376793 2026-06-30 0001376793 2025-07-01 2025-09-30 0001376793 us-gaap:CommonStockMember 2026-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001376793 us-gaap:RetainedEarningsMember 2026-06-30 0001376793 us-gaap:CommonStockMember 2025-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001376793 us-gaap:RetainedEarningsMember 2025-06-30 0001376793 2025-06-30 0001376793 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001376793 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001376793 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001376793 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001376793 us-gaap:CommonStockMember 2026-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001376793 us-gaap:RetainedEarningsMember 2026-09-30 0001376793 us-gaap:CommonStockMember 2025-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001376793 us-gaap:RetainedEarningsMember 2025-09-30 0001376793 2025-09-30 0001376793 CVAT:TenderOfferAgreementMember 2026-08-13 2026-08-14 0001376793 CVAT:OneRentalCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001376793 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CVAT:VendorOneMember 2026-07-01 2026-09-30 0001376793 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CVAT:VendorTwoMember 2026-07-01 2026-09-30 0001376793 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CVAT:VendorThreeMember 2026-07-01 2026-09-30 0001376793 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CVAT:VendorOneMember 2025-07-01 2026-06-30 0001376793 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CVAT:VendorTwoMember 2025-07-01 2026-06-30 0001376793 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001376793 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001376793 CVAT:ConvertibleNoteMember 2026-07-01 2026-09-30 0001376793 CVAT:ConvertibleNoteMember 2025-07-01 2025-09-30 0001376793 CVAT:BridgeNoteOneMember CVAT:BridgeNotePayableMember 2026-09-30 0001376793 CVAT:BridgeNoteOneMember CVAT:BridgeNotePayableMember 2026-06-30 0001376793 CVAT:BridgeNoteTwoMember CVAT:BridgeNotePayableMember 2026-09-30 0001376793 CVAT:BridgeNoteTwoMember CVAT:BridgeNotePayableMember 2026-06-30 0001376793 CVAT:BridgeNotePayableMember 2026-09-30 0001376793 CVAT:BridgeNotePayableMember 2026-06-30 0001376793 CVAT:BridgeNotePayableMember 2026-05-11 0001376793 CVAT:BridgeNotePayableMember 2026-05-10 2026-05-11 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2026-10-29 2026-10-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2026-11-29 2026-11-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2026-12-29 2026-12-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-01-29 2027-01-30 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-02-27 2027-02-28 0001376793 CVAT:BridgeNotePayableMember 2026-07-13 0001376793 CVAT:BridgeNotePayableMember 2026-07-10 2026-07-13 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-01-14 2027-01-15 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-02-10 2027-02-15 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-03-10 2027-03-15 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-04-10 2027-04-15 0001376793 CVAT:BridgeNotePayableMember us-gaap:SubsequentEventMember 2027-05-10 2027-05-15 0001376793 srt:ChiefExecutiveOfficerMember 2026-01-09 2026-05-04 0001376793 us-gaap:ConvertibleNotesPayableMember 2026-09-30 0001376793 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2026-01-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2026-07-01 2026-09-30 0001376793 CVAT:XyraCorpConvertibleNotesMember 2026-09-30 0001376793 CVAT:XyraCorpConvertibleNotesMember us-gaap:SubsequentEventMember 2026-12-05 0001376793 us-gaap:MeasurementInputSharePriceMember 2026-07-01 2026-09-30 0001376793 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-07-01 2026-09-30 0001376793 us-gaap:MeasurementInputPriceVolatilityMember 2026-07-01 2026-09-30 0001376793 us-gaap:MeasurementInputExpectedTermMember 2026-07-01 2026-09-30 0001376793 CVAT:MeasurementInputNumberOfSharesIssuableMember 2026-07-01 2026-09-30 0001376793 CVAT:EIDLMember 2026-09-30 0001376793 CVAT:EIDLMember 2026-06-30 0001376793 CVAT:EIDLMember 2020-07-01 2020-07-31 0001376793 CVAT:EIDLMember 2020-07-31 0001376793 us-gaap:CommonStockMember 2026-08-01 2026-09-30 0001376793 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001376793 us-gaap:CommonStockMember 2026-09-01 2026-09-30 0001376793 CVAT:WarrantHoldersMember us-gaap:WarrantMember CVAT:CashlessExerciseOfWarrantsMember 2026-09-09 2026-09-10 0001376793 CVAT:WarrantHoldersMember CVAT:CashlessExerciseOfWarrantsMember us-gaap:CommonStockMember 2026-09-09 2026-09-10 0001376793 us-gaap:WarrantMember 2026-09-30 0001376793 us-gaap:WarrantMember 2026-06-30 0001376793 us-gaap:WarrantMember 2025-07-01 2026-06-30 0001376793 CVAT:WarrantPrice1Member 2026-09-30 0001376793 CVAT:WarrantPrice1Member 2026-07-01 2026-09-30 0001376793 CVAT:WarrantPrice2Member 2026-09-30 0001376793 CVAT:WarrantPrice2Member 2026-07-01 2026-09-30 0001376793 CVAT:WarrantPrice3Member 2026-09-30 0001376793 CVAT:WarrantPrice3Member 2026-07-01 2026-09-30 0001376793 CVAT:WarrantPrice4Member 2026-09-30 0001376793 CVAT:WarrantPrice4Member 2026-07-01 2026-09-30 0001376793 us-gaap:WarrantMember 2026-09-30 0001376793 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001376793 us-gaap:AllOtherSegmentsMember 2026-07-01 2026-09-30 0001376793 us-gaap:AllOtherSegmentsMember 2025-07-01 2025-09-30 iso4217:USD shares iso4217:USD shares pure CVAT:Integer false --06-30 2027 Q1 0001376793

10-Q true false 2026-09-30 000-53239 Cavitation Technologies, Inc. NV 20-4907818 10019 CANOGA AVENUE CHATSWORTH CA 91311 818 718-0905 Yes Yes Non-accelerated Filer true false false 324320459

94000

17000

13000

17000

107000

34000

11000

118000

45000

158000

174000

40000

19000

157000

129000

175000

103000

115000 115000

45000

34000

17000

14000

707000

588000

150000

857000

738000

0.001

10000000

0.001

1000000000

324320459

317220739

324000

317000

27509000

27354000

-28572000

-28364000

-739000

-693000

118000

45000

3000

165000

245000

7000

165000

252000

-165000

-249000

-40000

-9000

-3000

-208000

-258000

-0.00

319229936

289156340

317220739

317000

27354000

-28364000

-693000

4666665

5000

135000

140000

500000

22000

1933055

2000

-2000

-208000

324320459

324000

27509000

-28572000

-739000

289156340

289000

26740000

-26960000

69000

-258000

289156340

289000

26740000

-27218000

-189000

-208000

-258000

18000

-3000

-0

22000

-0

-5000

-4000

-13000

-16000

14000

28000

21000

7000

-128000

-219000

140000

65000

205000

77000

-219000

17000

249000

94000

30000

2000

<p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zSad47WqKi04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 1 – Organization and Summary of Significant Accounting Policies Cavitation Technologies, Inc. (“the Company,” “CTi,” “we,” “us,” “CVAT,” and “our”) is a Nevada corporation originally incorporated in January 2007 under the name BioEnergy, Inc. The Company had originally developed, patented, and commercialized proprietary technology, which has subsequently been sold to Desmet Ballestra in October 2024, pursuant to a patent assignment and license back agreement. Tender Offer European Guarantee Services S.à.r.l On August 14, 2026, the Company received a tender offer agreement with European Guarantee Services S.à.r.l. (“EGS”), pursuant to which EGS agreed to acquire, or seek to acquire, all outstanding shares of the Company’s common stock for $35 million in cash, less certain indebtedness and accrued liabilities (the “Net Purchase Price”). EGS is required to commence the tender offer within 10 business days after satisfying applicable SEC regulatory requirements. The offer will remain open for at least 60 business days to allow shareholders to evaluate the Agreement and related offer documents. In October 2026, the tender offer was terminated. BrightFlixx Finance Luxembourg S.A On October 9, 2026, the Company and Alchemy Beverages Inc., a privately held Delaware corporation in which the Company holds a 17% equity stake, entered into definitive tender offer agreements with BrightFlixx Finance Luxembourg S.A. (“BrightFlixx”), a Luxembourg société anonyme. One agreement relates to the Company (the “BF-CVAT Agreement”), and the other relates to Alchemy Beverages Inc. (the “BF-ABI Agreement”). Together, the agreements are referred to as the “BrightFlixx Agreements.” The BF-CVAT Agreement replaces the Company’s tender offer agreement dated August 14, 2026, with European Guarantee Services S.à r.l. (“EGS”), and the BF-ABI Agreement replaces the tender offer agreement dated August 19, 2026, between EGS and Alchemy. Under the BF-CVAT Agreement, BrightFlixx intends to commence a cash tender offer to acquire all outstanding shares of the Company’s common stock for an aggregate purchase price of $35 million, less the Company’s outstanding liabilities. The purchase price per share will be determined based on the total number of outstanding shares as of a Record Date, which will be established 45 business days after commencement of the tender offer. As of the date of this report, the tender offer has not commenced. The offer is initially scheduled to expire 60 business days after commencement, subject to extensions, including an extension to provide shareholders at least 30 business days to evaluate the final offer price. Completion of the transaction is subject to customary closing conditions, including the valid tender of at least 90% of the outstanding shares, CFIUS regulatory approval or a no-further-action determination, and the concurrent consummation of the Alchemy tender offer. The agreement also includes customary representations, warranties, covenants, and termination provisions. The proposed tender offer remains subject to regulatory review and approval and has not yet been finalized or consummated. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited condensed consolidated financial statements, during the three months ended September 30, 2026, the Company incurred a net loss of $208,000, used cash in operations of $128,000 and as of September 30, 2026, the Company had a stockholders’ deficit of $739,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2026 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that may result from its inability to continue as a going concern. As of September 30, 2026, the Company has cash in the amount of $94,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by using its Reserved Grant Back License to apply the technology to: (i) water and wastewater processing, recovery, recycling and purification (including oilfield wastewater) and (ii) manufacture, distillation, brewing, enhancements, sale and marketing of alcoholic beverages, together the Licensed Fields. The Company has a worldwide, exclusive, transferable and royalty-free license and right to design, build, use, export, improve, sell and market Nano Reactor® devices and systems (and products) that incorporate or utilize Nano Reactor® devices, in each case within the Licensed Fields, and to continue to use the Nano Reactor® trademark in connection with its business, systems and products within the Licensed Fields. In addition, the Company will continue to develop its (i) water treatment and remediation in the Permian Basin; (ii) water remediation and disinfection in agriculture; (iii) business venture with Alchemy Beverages, Inc. to develop a smart home kitchen appliance for alcoholic beverages; (iv) hydro plasma technology, and (v) non-thermal plasma for immersion cooling in crypto mining and high-density data centers, in order to generate revenues and sustain operations. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. Management estimates that the Company’s existing cash will not be sufficient to sustain its operations for the twelve months following the issuance of these financial statements. The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiaries Hydrodynamic Technology, Inc., and Xyra Corp. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include valuation of our equity method investments, and derivative liabilities, assumptions used in valuing our stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. The Company uses Level 3 inputs for its valuation methodology for the derivative liabilities as their fair values were determined by using a variable option pricing model. The Company’s derivative liabilities are adjusted to reflect fair value at each reporting date, with any increase or decrease in the fair value being recorded in the statement of operations. Fair Value Measurement FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. As of September 30, 2026 and June 30, 2026, the carrying value of certain accounts such as accounts receivable, accounts payable, accrued expenses and accrued payroll approximate their fair value due to the short-term nature of such instruments. The carrying value of our note payable approximates its fair value due to the interest rate of the note. The Company’s derivative liabilities at September 30, 2026 were determined using Level 3 inputs. Revenue Recognition The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. For the license fee revenue, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement and collectability is certain. The Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer and collectability is certain. In addition, the Company also recognizes revenues from short-term rental of Nano Reactors. Rental revenue is recognized over the term of the agreement and when collectability is certain. During the three months ended September 30, 2026, the Company recognized no revenue. Share-Based Compensation We periodically issue warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. Net Loss Per Share The Company’s computation of net loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. There were no adjustments to net loss required for purposes of computing diluted earnings per share. At September 30, 2026 and 2025, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive as the exercise price of these warrants was greater than the stock price of the Company’s common stock. <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2nKBVU4Bbuf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of anti-dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTh8ILQBNXUa" style="width: 13%; text-align: right" title="Antidilutive shares">14,269,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7ZqiPhyNnOi" style="width: 13%; text-align: right" title="Antidilutive shares">49,041,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zPQVe30cBzEd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">1,320,845</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zUwW9iZMSa9l" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930_zb7RVWPuYjul" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">15,590,245</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250701__20250930_zxh7TGCTYe0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">49,041,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Concentrations During the three months ended September 30, 2025, we recorded <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneRentalCustomerMember_zAEyDlkDMtLl" title="Concentration risk percentage">100% of our revenue from one rental customer. We recognized no rental income for the three months ended September 30, 2026. As of September 30, 2026, three vendors accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorOneMember_zPsQhKJbJaRh" title="Concentration risk, percentage">22%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorTwoMember_zHPUVwXJ7bS" title="Concentration risk, percentage">14% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorThreeMember_zYSL7Zn4Ql6l" title="Concentration risk, percentage">12% of the Company’s accounts payable. As of June 30, 2026, two vendors accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorOneMember_zTI5fFxTbwZf" title="Concentration risk, percentage">18% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorTwoMember_zmI8IznAqIqk" title="Concentration risk, percentage">15% of the Company’s accounts payable. Segments The Company operates in one segment for the development and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s Chief Operating Decision Maker (CODM) has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base, single sales team, marketing department, customer service department, operations department, finance and accounting department to support its operations and similarities in economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in Note 9. Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

35000000

Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited condensed consolidated financial statements, during the three months ended September 30, 2026, the Company incurred a net loss of $208,000, used cash in operations of $128,000 and as of September 30, 2026, the Company had a stockholders’ deficit of $739,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2026 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that may result from its inability to continue as a going concern. As of September 30, 2026, the Company has cash in the amount of $94,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by using its Reserved Grant Back License to apply the technology to: (i) water and wastewater processing, recovery, recycling and purification (including oilfield wastewater) and (ii) manufacture, distillation, brewing, enhancements, sale and marketing of alcoholic beverages, together the Licensed Fields. The Company has a worldwide, exclusive, transferable and royalty-free license and right to design, build, use, export, improve, sell and market Nano Reactor® devices and systems (and products) that incorporate or utilize Nano Reactor® devices, in each case within the Licensed Fields, and to continue to use the Nano Reactor® trademark in connection with its business, systems and products within the Licensed Fields. In addition, the Company will continue to develop its (i) water treatment and remediation in the Permian Basin; (ii) water remediation and disinfection in agriculture; (iii) business venture with Alchemy Beverages, Inc. to develop a smart home kitchen appliance for alcoholic beverages; (iv) hydro plasma technology, and (v) non-thermal plasma for immersion cooling in crypto mining and high-density data centers, in order to generate revenues and sustain operations. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. Management estimates that the Company’s existing cash will not be sufficient to sustain its operations for the twelve months following the issuance of these financial statements. The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

-208000

-128000

-739000

94000

Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiaries Hydrodynamic Technology, Inc., and Xyra Corp. Intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include valuation of our equity method investments, and derivative liabilities, assumptions used in valuing our stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.

Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. The Company uses Level 3 inputs for its valuation methodology for the derivative liabilities as their fair values were determined by using a variable option pricing model. The Company’s derivative liabilities are adjusted to reflect fair value at each reporting date, with any increase or decrease in the fair value being recorded in the statement of operations.

Fair Value Measurement FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. As of September 30, 2026 and June 30, 2026, the carrying value of certain accounts such as accounts receivable, accounts payable, accrued expenses and accrued payroll approximate their fair value due to the short-term nature of such instruments. The carrying value of our note payable approximates its fair value due to the interest rate of the note. The Company’s derivative liabilities at September 30, 2026 were determined using Level 3 inputs.

Revenue Recognition The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. For the license fee revenue, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement and collectability is certain. The Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer and collectability is certain. In addition, the Company also recognizes revenues from short-term rental of Nano Reactors. Rental revenue is recognized over the term of the agreement and when collectability is certain. During the three months ended September 30, 2026, the Company recognized no revenue.

Share-Based Compensation We periodically issue warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

Net Loss Per Share The Company’s computation of net loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. There were no adjustments to net loss required for purposes of computing diluted earnings per share. At September 30, 2026 and 2025, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive as the exercise price of these warrants was greater than the stock price of the Company’s common stock. <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2nKBVU4Bbuf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of anti-dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTh8ILQBNXUa" style="width: 13%; text-align: right" title="Antidilutive shares">14,269,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7ZqiPhyNnOi" style="width: 13%; text-align: right" title="Antidilutive shares">49,041,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zPQVe30cBzEd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">1,320,845</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zUwW9iZMSa9l" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930_zb7RVWPuYjul" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">15,590,245</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250701__20250930_zxh7TGCTYe0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">49,041,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z2nKBVU4Bbuf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of anti-dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTh8ILQBNXUa" style="width: 13%; text-align: right" title="Antidilutive shares">14,269,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z7ZqiPhyNnOi" style="width: 13%; text-align: right" title="Antidilutive shares">49,041,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zPQVe30cBzEd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">1,320,845</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250701__20250930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zUwW9iZMSa9l" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260701__20260930_zb7RVWPuYjul" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">15,590,245</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250701__20250930_zxh7TGCTYe0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">49,041,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14269400

49041323

1320845

15590245

49041323

Concentrations During the three months ended September 30, 2025, we recorded <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneRentalCustomerMember_zAEyDlkDMtLl" title="Concentration risk percentage">100% of our revenue from one rental customer. We recognized no rental income for the three months ended September 30, 2026. As of September 30, 2026, three vendors accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorOneMember_zPsQhKJbJaRh" title="Concentration risk, percentage">22%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorTwoMember_zHPUVwXJ7bS" title="Concentration risk, percentage">14% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20260701__20260930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorThreeMember_zYSL7Zn4Ql6l" title="Concentration risk, percentage">12% of the Company’s accounts payable. As of June 30, 2026, two vendors accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorOneMember_zTI5fFxTbwZf" title="Concentration risk, percentage">18% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20250701__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--VendorTwoMember_zmI8IznAqIqk" title="Concentration risk, percentage">15% of the Company’s accounts payable.

0.22

0.14

0.12

0.18

0.15

Segments The Company operates in one segment for the development and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s Chief Operating Decision Maker (CODM) has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base, single sales team, marketing department, customer service department, operations department, finance and accounting department to support its operations and similarities in economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in Note 9.

Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Note 2 – Bridge Notes Payable <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfBridgeNotePayableTableTextBlock_zv2GTS3qtXKk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Bridge Note Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of bridge note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20260930__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zybQqRFHBsJ6" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zFHRgwzHWA34" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Principal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteOneMember_zTvHmM42auD2" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Bridge Note #1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">111,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">111,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember_zaEfRVzQbSdk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Bridge Note #2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_c20260630__us-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zhof24gWqIj6" style="border-bottom: Black 1pt solid; text-align: right" title="Principal">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_zapFYmxrps5k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">185,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_c20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_z47U2U0m0XRj" style="border-bottom: Black 1pt solid; text-align: right" title="Principal, subtotal">111,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteOneMember_zw6aTvPY8vci" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Bridge Note #1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember_z0wcR6T9Ehm7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Bridge Note #2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_c20260630__us-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zDDF03vMQVR5" style="text-align: right" title="Debt discount">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_z1P8ZIG3u6Qj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_zkCgqRNa7Zn3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_z9S8s6iL6mn7" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount, subtotal">(8,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShortTermBorrowings_iI_d0_z4v0EQG0neA8" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Bridge notes payable, Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">175,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">103,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> On May 11, 2026, the Company entered into a bridge note with a lender for $111,000 for net proceeds of $100,000, after direct expenses of $11,000, which was recorded as a debt discount to be amortized over the term of the note. The note matures on March 11, 2027, ten months after issuance date. The bridge note bears interest at 24% of the value of the bridge note ($27,000) regardless of repayment date, resulting in an effective interest rate of 30.2% based on the repayment schedule. Additional tranches of funding are available up to a total of $500,000 during the <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20260510__20260511__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zQZqWsu2eB34" title="Line of credit expiration period">12 months ending May 11, 2027. The bridge note is repayable in five instalments, $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20261029__20261030__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDzlMwnh0mH8" title="Debt periodic payment">70,000 on October 30, 2026, $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20261129__20261130__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwhbrDpVI3Sl"><span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20261229__20261230__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zplNVtp2SyW3"><span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_c20270129__20270130__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA08pPfJy2vi"><span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20270227__20270228__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW7f7HGXQxT2">17,000 on each of November 30, 2026, December 30, 2026, January 30, 2027 and February 28, 2027. On July 13, 2026, the Company entered into a similar bridge note with the same lender for $74,000 for net proceeds of $65,000, after direct expenses of $9,000, which was recorded as a debt discount to be amortized over the term of the note. The note matures on May 15, 2027, ten months after issuance date. The bridge note bears interest at 24% of the value of the bridge note ($17,640) regardless of repayment date, resulting in an effective interest rate of 29.7% based on the repayment schedule. Additional tranches of funding are available up to a total of $500,000 during the <span id="xdx_904_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20260710__20260713__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zdKlnQWmMGoh" title="Line of credit expiration period">12 months ending May 11, 2027. The bridge note is repayable in five instalments, $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20270114__20270115__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIyJ5VLnU7q7" title="Debt periodic payment">46,000 on January 15, 2027, and $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20270210__20270215__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFRaby60zJqe"><span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20270310__20270315__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd7oOjf8g0Q6"><span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20270410__20270415__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF36pHx92ABf"><span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_c20270510__20270515__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zC1ELMAxY7m5">11,400 on each of February 15, 2027, March 15, 2027, April 15, 2027 and May 15, 2027. In the event of default, the principal balance of the notes will be increased by 150%, and after the expiry of 180 days, the notes may be converted into shares of common stock at the option of the lender, at a conversion price of 65% of the lowest closing bid price of the Company’s common stock during the ten-day trading period prior to conversion, with conversion limited to 4.99% of the total issued and outstanding common stock at the time of conversion. The notes may be prepaid up to 180 days from date of issuance with prepayment discounts ranging from 95% to 98% of the total amount outstanding, including interest.

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfBridgeNotePayableTableTextBlock_zv2GTS3qtXKk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Bridge Note Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of bridge note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20260930__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zybQqRFHBsJ6" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zFHRgwzHWA34" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Principal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteOneMember_zTvHmM42auD2" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Bridge Note #1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">111,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">111,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember_zaEfRVzQbSdk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Bridge Note #2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_c20260630__us-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zhof24gWqIj6" style="border-bottom: Black 1pt solid; text-align: right" title="Principal">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_d0_zapFYmxrps5k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">185,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_c20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_z47U2U0m0XRj" style="border-bottom: Black 1pt solid; text-align: right" title="Principal, subtotal">111,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteOneMember_zw6aTvPY8vci" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Bridge Note #1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_hus-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember_z0wcR6T9Ehm7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Bridge Note #2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_c20260630__us-gaap--DebtInstrumentAxis__custom--BridgeNoteTwoMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_zDDF03vMQVR5" style="text-align: right" title="Debt discount">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_z1P8ZIG3u6Qj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_zkCgqRNa7Zn3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeNotePayableMember_z9S8s6iL6mn7" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount, subtotal">(8,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShortTermBorrowings_iI_d0_z4v0EQG0neA8" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Bridge notes payable, Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">175,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">103,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

111000

74000

185000

111000

8000

11000

9000

-0

7000

3000

10000

8000

175000

103000

111000

100000

11000

2027-03-11

0.24

27000

0.302

500000

P12M

2027-05-11

70000

17000

74000

65000

9000

2027-05-15

0.24

17640

0.297

500000

P12M

2027-05-11

46000

11400

Note 3 – Promissory Notes Payable – Related Party <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfNotePayableRelatedPartyTableTextBlock_z3NQ5SNcm7L9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Promissory Notes payable - Related party (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of note payable- related party</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_498_20260930_zmULgYEDCUMk" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_49D_20260630_z6JNH0JU0d65" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; font-weight: bold">Principal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NotesPayableRelatedParty_iI_d0_zkLvTPWNIKXc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Promissory notes payable - related party</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">115,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">115,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> Between January 9, 2026 and May 4, 2026, the Company entered into five promissory note agreements with an entity associated with the Company’s CEO, wherein the entity advanced the Company an aggregate of $115,000 to fund operations. The promissory notes are unsecured, bear interest at 8% per annum and mature in twelve months after advance, as amended. <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfNotePayableRelatedPartyTableTextBlock_z3NQ5SNcm7L9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Promissory Notes payable - Related party (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of note payable- related party</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_498_20260930_zmULgYEDCUMk" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_49D_20260630_z6JNH0JU0d65" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; font-weight: bold">Principal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NotesPayableRelatedParty_iI_d0_zkLvTPWNIKXc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Promissory notes payable - related party</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">115,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">115,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 115000 115000

115000

0.08

Note 4 – Convertible Notes Payable <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zVAAV35u7R5e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Note (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of convertible notes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20260930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zlYhVgF7hi3" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20260630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zNYjiK7lsx65" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Principal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_d0_z3AggpGp7gj1" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 1pt">Convertible note payable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_zSIsjq9lYuh5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(38,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_zfeSbejoxrZ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_zF6DpCpOYUpb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_d0_zqQ3AnbZtiV4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">45,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> In December 2025 and January 2026, Xyra Corp., the Company’s wholly owned subsidiary, issued three one-year convertible notes, amounting to $60,000, with maturity dates from <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20260701__20260930__us-gaap--LongtermDebtTypeAxis__custom--XyraCorpConvertibleNotesMember_zkaeoxWKdy81" title="Debt maturity date, start range">December 5, 2026 to <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20260701__20260930__us-gaap--LongtermDebtTypeAxis__custom--XyraCorpConvertibleNotesMember_zka0TPQkYbA3" title="Debt maturity date, end range">January 30, 2027, with a stated annual interest rate of 8%. The Company, prior to the maturity date, has the option to extend the maturity date of the note by an additional six months. The note may be prepaid at any time without penalty. The holder has an option to convert the principal of the convertible note into Xyra common stock for a period of six months once notified by the Company, in writing, of a public listing on any recognized U.S. national or regional stock exchange or on any of the markets operated by the OTC Markets Group. The conversion price will be 50% of the 5-day average closing price immediately prior to conversion. Xyra, at its sole discretion, may allow the conversion of unpaid interest into Xyra common stock for the same period allowed for the conversion of the principal. Should Xyra not achieve a public offering by December 5, 2026, the holder has the option to convert the principal outstanding into common shares of the Company for a period of six months from December 5, 2026. The conversion price will be the greater of 80% of $0.06 or the current CTI market price. The market price will be determined as the weighted average of the high and low trading prices of the Company stock over a 5-day period. The Company, at its sole discretion, may allow the conversion of interest at any time after the maturity date and during any extended period exercised by Xyra. The Company analyzed the conversion options for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined that the conversion options should be accounted for as a derivative liability since they do not have an explicit limit to the number of shares to be delivered upon settlement of the conversion option (see Note 5). The cumulative fair value of the derivative liability upon issuance of the convertible notes payable at issuance date amounted to $<span id="xdx_90D_eus-gaap--DerivativeLiabilities_iI_c20261205__us-gaap--LongtermDebtTypeAxis__custom--XyraCorpConvertibleNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFZtNBTM9dX5" title="Derivative liability">38,000, and accounted for as a debt discount, which is being amortized to interest expense over the term of the corresponding notes payable.

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zVAAV35u7R5e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Note (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of convertible notes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20260930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zlYhVgF7hi3" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20260630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zNYjiK7lsx65" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Principal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_d0_z3AggpGp7gj1" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; padding-bottom: 1pt">Convertible note payable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Debt Discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di0_zSIsjq9lYuh5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(38,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_d0_zfeSbejoxrZ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di0_zF6DpCpOYUpb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_d0_zqQ3AnbZtiV4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">45,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

60000

26000

38000

11000

12000

15000

26000

45000

34000

60000

2026-12-05

2027-01-30

0.08

38000

Note 5 – Derivative Liability In December 2025 and January 2026, the Company issued convertible notes payable whose conversion options are being accounted for as a derivative liability pursuant to ASC 815, Derivatives and Hedging (see Note 4). The derivative liability is remeasured to fair value at each reporting period, and the change in the fair value is recognized in earnings in the accompanying statements of operations. The Company estimated the fair value of the conversion option derivative liability using a variable option pricing model. The following table provides a roll-forward of the derivative liability measured at fair value on a recurring basis using unobservable Level 3 inputs for the period ended September 30, 2026, as follows: <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zKh04XD1xzn1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details - Rollforward of derivative liability)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of roll forward of derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Fair value of derivative liability at beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20260701__20260930_zPUJUmBMOSPi" style="width: 13%; text-align: right" title="Fair value of derivative liability at beginning of the period">14,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20260701__20260930_zYwYdxS7PtL1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Fair value of derivative liability at period end</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20260701__20260930_zoaaUYRuZuId" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability at period end">17,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following are the average inputs used by the Company in the valuation of the derivative liability: <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zRnXL3g7F8Q2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Derivative Liability (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td style="width: 79%">Schedule of valuation of derivative liability</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Stock price</td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zzFQlUhG3uY8" title="Assumption used">0.048</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQBUdbtIJu2g" title="Assumption used">4.11% to 4.27%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zdm4vxUUU2x1" title="Assumption used">137.7% to 200.0%</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expected life in months</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zdMfgkWaABI9" title="Assumption used">2 to 4 months</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Number of common stock issuable</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputNumberOfSharesIssuableMember_zcJZlqKKeMMg" title="Assumption used">1,295,639 to 1,320,845</td> <td> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zKh04XD1xzn1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details - Rollforward of derivative liability)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of roll forward of derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Fair value of derivative liability at beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20260701__20260930_zPUJUmBMOSPi" style="width: 13%; text-align: right" title="Fair value of derivative liability at beginning of the period">14,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20260701__20260930_zYwYdxS7PtL1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Fair value of derivative liability at period end</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20260701__20260930_zoaaUYRuZuId" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of derivative liability at period end">17,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14000

3000

17000

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfServicingLiabilitiesAtFairValueTextBlock_zRnXL3g7F8Q2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Derivative Liability (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td style="width: 79%">Schedule of valuation of derivative liability</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Stock price</td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zzFQlUhG3uY8" title="Assumption used">0.048</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQBUdbtIJu2g" title="Assumption used">4.11% to 4.27%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zdm4vxUUU2x1" title="Assumption used">137.7% to 200.0%</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expected life in months</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zdMfgkWaABI9" title="Assumption used">2 to 4 months</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Number of common stock issuable</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20260701__20260930__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputNumberOfSharesIssuableMember_zcJZlqKKeMMg" title="Assumption used">1,295,639 to 1,320,845</td> <td> </td></tr> </table>

0.048

4.11% to 4.27%

137.7% to 200.0%

2 to 4 months

1,295,639 to 1,320,845

Note 6 – Note Payable <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zDVifQDz92nb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Note Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of notes payable</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; font-weight: bold">Principal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Note payable - EIDL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20260930__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_z4jaoTBhHPVf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20260630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_zUSxTRrcb47j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> In July 2020, the Company received a loan of $150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of 3.75% per annum and is secured by all tangible and intangible property of the Company. Pursuant to the Company’s agreement with the SBA in the prior year that cured prior payment defaults and past due balances, monthly installment payments are first being applied to accrued and unpaid interest. As of September 30, 2026 and June 30, 2026, the outstanding balance of the note payable was $150,000 and $150,000, respectively.

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zDVifQDz92nb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Note Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of notes payable</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; font-weight: bold">Principal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Note payable - EIDL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20260930__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_z4jaoTBhHPVf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20260630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_zUSxTRrcb47j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes payable">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

150000

0.0375

150000

Note 7 – Stockholders’ Deficit Common stock During August and September 2026, the Company entered into agreements with five accredited investors whereby the investors subscribed for 4,666,665 shares of common stock at a price of $0.03 per share for aggregate proceeds of $140,000. As part of the agreements, certain investors agreed to forfeit an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcewq2yg7rZ6" title="Warrants forfeited">2,499,999 equity classified warrants granted to them in May 2026, which had an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcsepTbHsngh" title="Warrants forfeited, weighted average exercise price">0.045 per share. Pursuant to ASC 505, Equity, and other applicable accounting guidance, the cancellation of these equity-classified warrants in connection with the issuance of common stock for cash was accounted for as a single equity transaction. The cancellation resulted in an offsetting adjustment to additional paid-in capital (“APIC”) and did not affect the Company’s consolidated net loss. In September 2026, the Company issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260901__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_znjE3IoRJLu2" title="Issued shares for services">500,000 shares of common stock to a consultant for services rendered. The common stock issued was valued at fair market value on the grant date at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260901__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9mlqomnZiFl" title="Issued shares for services, value">22,000. On September 10, 2026, a warrant holder exercised warrants for an aggregate of <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20260909__20260910__srt--CounterpartyNameAxis__custom--WarrantHoldersMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zTGZiHnvF3Ih" title="Stock converted, shares converted">3,000,000 shares of common stock on a cashless basis in accordance with the terms of the warrant agreements. As a result, the Company issued <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20260909__20260910__srt--CounterpartyNameAxis__custom--WarrantHoldersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zISbsgYs68Vj" title="Stock converted, shares issued">1,933,055 shares of common stock. Warrants A summary of the Company’s warrant activity as of September 30, 2026 is as follows: <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zIFpsNRLOT5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Schedule of warrant activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Outstanding at June 30, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKw4m4y88WGj" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">31,571,784</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYozLiG0zkg" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price, beginning balance">0.056</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zabEukEojmob" title="Weighted average remaining contractual life">2.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkEFoUFPlbz" style="text-align: right" title="Warrants granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNq2h4j3urSg" style="text-align: right" title="Warrants granted, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_di0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaZMvKv2IH1a" style="text-align: right" title="Warrants exercised">(3,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSLUMBXeb7ib" style="text-align: right" title="Warrants exercised, weighted average exercise price">0.017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zR0m9MA6mR8d" style="text-align: right" title="Warrants forfeited">(2,499,999</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzm2mCMX9Nmf" style="text-align: right" title="Warrants forfeited, weighted average exercise price">0.045</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">- Expired/retired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriod_iN_di0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqzCrkrzkQ6d" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired/retired">(11,802,385</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za0B84rwQlej" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired/retired, weighted average exercise price">0.090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Outstanding at September 30, 2026</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCkBpikjNuS" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding, ending balance">14,269,400</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2dP3f1Frcig" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding, weighted average exercise price, ending balance">0.038</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeFW3jzAFIr" title="Weighted average remaining contractual life">3.57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> As of September 30, 2026, the intrinsic value of these stock purchase warrants amounted to $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGb0Dc643M5f" title="Intrinsic value of warrants">139,200. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zs5JwxO00Tth" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of warrants outstanding and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 15%; text-align: right">$0.013</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zoRw61NA3cBe" style="width: 13%; text-align: right" title="Warrants outstanding">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_z7zambTYLzi3" title="Weighted average remaining life, warrants outstanding">3.14</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_z5R3TLkR8SR" style="width: 13%; text-align: right" title="Weighted average exercise price">0.013</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_ziYOEyp9WBba" style="width: 13%; text-align: right" title="Warrants exercisable">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zjo7EOO5oBlf" title="Weighted average remaining life, warrants exercisable">3.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">$0.017</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zE7tQbclLekb" style="text-align: right" title="Warrants outstanding">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zbnvjSvyLrdj" title="Weighted average remaining life, warrants outstanding">3.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zQqUb1Aeybuh" style="text-align: right" title="Weighted average exercise price">0.017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zjkR2Jymotk6" style="text-align: right" title="Warrants exercisable">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zyFBOmVm1Ne8" title="Weighted average remaining life, warrants exercisable">3.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: right">$0.030</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zLQNncRjTPe8" style="text-align: right" title="Warrants outstanding">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zMOYMAJx40Sl" title="Weighted average remaining life, warrants outstanding">3.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zpRBDGHzumu6" style="text-align: right" title="Weighted average exercise price">0.030</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zxeUqERaxzab" style="text-align: right" title="Warrants exercisable">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zCd2SdlZiD31" title="Weighted average remaining life, warrants exercisable">3.26</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 1pt">$0.060</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zzHFkwUXgEhk" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding">5,769,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zpmK2aYoAhj" title="Weighted average remaining life, warrants outstanding">4.02</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_znOWRy9niz56" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">0.060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zYYSeC0G8ZOd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable">5,769,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zZLoI6IZehK7" title="Weighted average remaining life, warrants exercisable">4.02</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zOK8QbDee7mb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding">14,269,400</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zhZFZUJDBVia" title="Weighted average remaining life, warrants outstanding">3.57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zQyPG3g0isAh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Weighted average exercise price">0.038</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zkq7OnkToI5g" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants exercisable">14,269,400</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_z6vQ8TEtZ2ah" title="Weighted average remaining life, warrants exercisable">3.57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

4666665

140000

2499999

0.045

500000

22000

3000000

1933055

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zIFpsNRLOT5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Schedule of warrant activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Outstanding at June 30, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKw4m4y88WGj" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">31,571,784</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYozLiG0zkg" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price, beginning balance">0.056</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zabEukEojmob" title="Weighted average remaining contractual life">2.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkEFoUFPlbz" style="text-align: right" title="Warrants granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNq2h4j3urSg" style="text-align: right" title="Warrants granted, weighted average exercise price">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_di0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaZMvKv2IH1a" style="text-align: right" title="Warrants exercised">(3,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSLUMBXeb7ib" style="text-align: right" title="Warrants exercised, weighted average exercise price">0.017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zR0m9MA6mR8d" style="text-align: right" title="Warrants forfeited">(2,499,999</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzm2mCMX9Nmf" style="text-align: right" title="Warrants forfeited, weighted average exercise price">0.045</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">- Expired/retired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriod_iN_di0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqzCrkrzkQ6d" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired/retired">(11,802,385</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za0B84rwQlej" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired/retired, weighted average exercise price">0.090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Outstanding at September 30, 2026</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCkBpikjNuS" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding, ending balance">14,269,400</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2dP3f1Frcig" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding, weighted average exercise price, ending balance">0.038</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeFW3jzAFIr" title="Weighted average remaining contractual life">3.57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

31571784

0.056

P2Y5M19D

3000000 0.017

2499999

0.045

11802385 0.090

14269400

0.038

P3Y6M25D

139200

<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zs5JwxO00Tth" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of warrants outstanding and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 15%; text-align: right">$0.013</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zoRw61NA3cBe" style="width: 13%; text-align: right" title="Warrants outstanding">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_z7zambTYLzi3" title="Weighted average remaining life, warrants outstanding">3.14</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_z5R3TLkR8SR" style="width: 13%; text-align: right" title="Weighted average exercise price">0.013</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_ziYOEyp9WBba" style="width: 13%; text-align: right" title="Warrants exercisable">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zjo7EOO5oBlf" title="Weighted average remaining life, warrants exercisable">3.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">$0.017</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zE7tQbclLekb" style="text-align: right" title="Warrants outstanding">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zbnvjSvyLrdj" title="Weighted average remaining life, warrants outstanding">3.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zQqUb1Aeybuh" style="text-align: right" title="Weighted average exercise price">0.017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zjkR2Jymotk6" style="text-align: right" title="Warrants exercisable">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zyFBOmVm1Ne8" title="Weighted average remaining life, warrants exercisable">3.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: right">$0.030</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zLQNncRjTPe8" style="text-align: right" title="Warrants outstanding">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zMOYMAJx40Sl" title="Weighted average remaining life, warrants outstanding">3.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zpRBDGHzumu6" style="text-align: right" title="Weighted average exercise price">0.030</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zxeUqERaxzab" style="text-align: right" title="Warrants exercisable">5,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zCd2SdlZiD31" title="Weighted average remaining life, warrants exercisable">3.26</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 1pt">$0.060</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zzHFkwUXgEhk" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding">5,769,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zpmK2aYoAhj" title="Weighted average remaining life, warrants outstanding">4.02</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_znOWRy9niz56" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">0.060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zYYSeC0G8ZOd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable">5,769,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice4Member_zZLoI6IZehK7" title="Weighted average remaining life, warrants exercisable">4.02</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zOK8QbDee7mb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding">14,269,400</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zhZFZUJDBVia" title="Weighted average remaining life, warrants outstanding">3.57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zQyPG3g0isAh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Weighted average exercise price">0.038</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_zkq7OnkToI5g" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants exercisable">14,269,400</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260701__20260930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__us-gaap--WarrantMember_z6vQ8TEtZ2ah" title="Weighted average remaining life, warrants exercisable">3.57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

2000000

P3Y1M20D

0.013

2000000 P3Y1M20D

1500000

P3Y4M28D

0.017

1500000 P3Y4M28D

5000000

P3Y3M3D

0.030

5000000 P3Y3M3D

5769400

P4Y7D

0.060

5769400 P4Y7D

14269400

P3Y6M25D

0.038

14269400 P3Y6M25D

Note 8 – Related Party Transactions Accrued Payroll and Payroll Taxes The Company accrues salaries and estimated payroll taxes due to a current shareholder and current officer and director of the Company. As of September 30, 2026 and June 30, 2026, the total accrued payroll and payroll taxes amounted to $157,000 and $129,000, respectively.

157000

129000

Note 9 – Segment Information The Company operates and manages its business as one reportable and operating segment. The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance. Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate the business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8v05tR5JKxa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of segment information</td><td> </td> <td colspan="2" id="xdx_49C_20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zB7sO1ukPyxi" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_499_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zi93HZYSaDPd" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_d0_zIkxpMSuSRG3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; padding-bottom: 1pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">3,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iN_di0_zSo7bGzbxpJd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_iN_di_z78bKjqA9eq5" style="vertical-align: bottom; background-color: White"> <td>Salaries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(66,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(123,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_zwvxQQnHrzzk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ProfessionalFees_iN_di_z9uFrcRciY0h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(35,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(51,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_iN_di_z18LW7JQYbyf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Rent expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--TravelAndEntertainmentExpense_iN_di0_zeuYvoU6EkC3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensation_iN_di0_zldStAPg7XQf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(22,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_iN_di_zY2ZJ2GqBNqh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(20,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(19,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iN_di_z9Hq6UdgiV8d" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Total operating expenses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(165,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(252,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zyANLDacNdyi" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Net operating loss</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(165,000</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(249,000</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_iN_di_z4Xo8EdFbPI8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Interest and other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di0_zuEis4kU9SN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zbPf3uZd0Apc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(208,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(258,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z8v05tR5JKxa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of segment information</td><td> </td> <td colspan="2" id="xdx_49C_20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zB7sO1ukPyxi" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_499_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zi93HZYSaDPd" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_d0_zIkxpMSuSRG3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; padding-bottom: 1pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">3,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iN_di0_zSo7bGzbxpJd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--SalariesAndWages_iN_di_z78bKjqA9eq5" style="vertical-align: bottom; background-color: White"> <td>Salaries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(66,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(123,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalAndContractServicesExpense_iN_di_zwvxQQnHrzzk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ProfessionalFees_iN_di_z9uFrcRciY0h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(35,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(51,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_iN_di_z18LW7JQYbyf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Rent expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--TravelAndEntertainmentExpense_iN_di0_zeuYvoU6EkC3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensation_iN_di0_zldStAPg7XQf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(22,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_iN_di_zY2ZJ2GqBNqh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(20,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(19,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iN_di_z9Hq6UdgiV8d" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Total operating expenses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(165,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(252,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zyANLDacNdyi" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Net operating loss</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(165,000</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(249,000</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_iN_di_z4Xo8EdFbPI8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Interest and other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di0_zuEis4kU9SN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zbPf3uZd0Apc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(208,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(258,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table>

3000

-0

7000

66000

123000

14000

25000

35000

51000

8000

9000

-0

18000

22000

-0

20000

19000

165000

252000

-165000

-249000

40000

9000

3000

-0

-208000

-258000

Note 10 – Commitments and Contingencies Royalty Agreements On July 1, 2008, the Company’s wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2026. On April 30, 2008 (as amended November 22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2026 and June 30, 2026, no patents have been granted in which this person is the legally named inventor. Other From time to time the Company may be named in claims arising in the ordinary course of business. Currently, there are no such legal proceedings that are pending against the Company or that involve the Company that, in the opinion of management, could reasonably be expected to have a material adverse effect on the Company’s business or financial condition.

Note 11 – Subsequent Events Other than disclosed above, the Company evaluated subsequent events for their potential impact on the condensed consolidated financial statements and disclosures through the date the condensed consolidated financial statements were issued and determined that no additional subsequent events occurred that were reasonably expected to impact the condensed consolidated financial statements presented herein.

false false false false